Abstract: The present invention relates to a system and methods for evaluating and tracking the operation of the menstrual cycle and treating undesirable trends associated with the menstrual cycle. Various aspects of the system and methods described herein rely upon the operation of diagnostic tests specially configured to evaluate a bodily fluid for the presence or absence of hormones or analytes, and more specifically configured to evaluate a bodily fluid for at least the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 ?g/mL-10 ?g/mL. The results from one or more diagnostic tests are interpreted in accordance with the teachings of the system.